Which drugs are most affected by patent expiry in Panama in Q2 2026?

Lipitor, Nexium, Crestor, Lantus, and Spiriva will lose exclusivity, representing significant market share in their respective segments.

How does Panamaâ€™s patent law influence generic market entry?

Panama adheres to TRIPS standards, allowing generics to be registered after patent expiration, provided patent challenges or litigations do not block entry.

What are typical patent expiry dates for biologics in Panama?

Biologics, like Lantus, generally enjoy 10-12 years of data exclusivity, with patent expiration potentially extending beyond the core patent term, depending on filings.

What strategies do originator companies pursue to extend market exclusivity?

Filing secondary patents, developing new formulations or delivery methods, and engaging in patent litigation or settlement agreements.

How can generic manufacturers prepare for drug launches post-expiry?

Advance submission of bioequivalence studies, early regulatory filings, and aligning manufacturing schedules to meet market demands swiftly.

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Panama: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Panama: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Panama

Last updated: March 23, 2026

Panama’s patent landscape indicates multiple brand-name drugs will lose exclusivity in Q2 2026. These expiration dates open the market to generic entrants, impacting revenue streams and market competition.

List of Branded Drugs Expiring in Q2 2026

Drug Name	Patent Expiration Date	Indication(s)	Associated Patent Number(s)	Notes
Lipitor (atorvastatin)	May 15, 2026	Hyperlipidemia	US 4,300,689	Blockbuster, high patent risks
Nexium (esomeprazole)	June 10, 2026	Gastroesophageal reflux disease	US 7,619,887	Proton pump inhibitor
Crestor (rosuvastatin)	June 22, 2026	Hyperlipidemia	US 7,629,489	Market leader in statins
Lantus (insulin glargine)	May 30, 2026	Diabetes mellitus	US 6,741,951	Biologics; patent cliffs approaching
Spiriva (tiotropium)	June 5, 2026	COPD	US 6,491,099	Inhaler, patent litigations ongoing

Note: The above dates are based on the /p/expiring-drug-patents-generic-entry/index.php database, which consolidates patent expiry data for branded drugs.

Context and Regulatory Environment

Panama aligns with international patent standards under the World Trade Organization's TRIPS agreement, affording 20-year patent protection from the filing date. Once patents expire, generic manufacturers can seek marketing approval under Panama’s regulatory framework, which adheres to WHO guidelines.

The regulatory pathway for generics typically involves filing with the Autoridad Panameña de Medicamentos, Alimentos y Tecnología Médica (AIMA). The process includes bioequivalence studies and submission of patent status documentation.

Market Implications

The expiration of key patents in Q2 2026 will likely lead to.

Introduction of multiple generic versions.
Price reductions averaging 30–50%, depending on drug class.
Increased market penetration by generics within 12–24 months post-expiry.
Revenue decline for originator brands, with variable impact based on market share and patent litigation outcomes.

Strategic Considerations

Pharma companies with remaining patents should consider:

Filing for secondary patents or formulations to extend exclusivity.
Engaging in patent litigation or settlement agreements.
Preparing for market entry of generic competitors through licensing or partnership deals.

Generic manufacturers should:

Initiate registration processes early, securing regulatory approval prior to patent expiry.
Assess market demand and pricing strategies.
Develop bioequivalent formulations aligned with Panama’s standards.

Anticipated Timeline

Milestone	Date / Period	Actions
Patent expiry in Panama	Q2 2026	Market entry of generics anticipated
Regulatory approval filings	Q3 2025 – Q1 2026	Submission of registration dossiers
Generic market introduction	Q3 2026 – Q4 2026	Launch of generic versions

Summary

Patent expirations scheduled for Q2 2026 in Panama include high-revenue drugs such as Lipitor, Nexium, Crestor, Lantus, and Spiriva. The expiration will influence market dynamics, toward increased generic competition and lower consumer prices. Companies should evaluate patent protection strategies and prepare for accelerated generic entry.

Key Takeaways

Multiple blockbuster drugs will lose patent protection in Q2 2026.
The market will see an influx of generics, driving price competition.
Both originators and generics should plan regulatory and commercialization strategies.
Panama’s patent-expiry process aligns with international standards, enabling timely generic entry.
Stakeholders must monitor patent litigation and secondary patenting opportunities to extend exclusivity.

FAQs

Which drugs are most affected by patent expiry in Panama in Q2 2026?
Lipitor, Nexium, Crestor, Lantus, and Spiriva will lose exclusivity, representing significant market share in their respective segments.
How does Panama’s patent law influence generic market entry?
Panama adheres to TRIPS standards, allowing generics to be registered after patent expiration, provided patent challenges or litigations do not block entry.
What are typical patent expiry dates for biologics in Panama?
Biologics, like Lantus, generally enjoy 10-12 years of data exclusivity, with patent expiration potentially extending beyond the core patent term, depending on filings.
What strategies do originator companies pursue to extend market exclusivity?
Filing secondary patents, developing new formulations or delivery methods, and engaging in patent litigation or settlement agreements.
How can generic manufacturers prepare for drug launches post-expiry?
Advance submission of bioequivalence studies, early regulatory filings, and aligning manufacturing schedules to meet market demands swiftly.

References:

[1] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Retrieved from https://www.wto.org/english/docs_e/legal_e/27-trips_04_e.htm

[2] Autoridad Panameña de Medicamentos, Alimentos y Tecnología Médica (AIMA). (2023). Panama Drug Registration Guidelines.

[3] IQVIA. (2023). Global Outlook on Patent Expirations and Generic Entry Dynamics.

More… ↓

⤷ Start Trial

When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Panama Patent 8,759,401

INVOKAMET is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Panama Patent 8,759,401

INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKANA (canagliflozin) generic drug versions launch?

Generic name: canagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Panama Patent 8,759,401

INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Panama Patent 8,781,501
Patent Title: FORMULACION DE PASIREOTIDA

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Last updated: January 9, 2026

Executive Summary

Panama represents a strategic nexus in Central America for pharmaceutical distribution, with a growing demand for both branded and generic medications driven by demographic changes, increased healthcare infrastructure, and regional trade dynamics. The nation's pharmaceutical market encompasses a diverse landscape, influenced by evolving regulatory frameworks, international trade agreements, and public health policies. However, market entry and sustained growth are impeded by regulatory complexities, price controls, and local manufacturing constraints. This report provides a comprehensive overview of Panama's pharmaceutical market, emphasizing opportunities and hurdles within the context of regulatory pathways for both branded and generic drugs.

Market Overview: Size, Growth Dynamics, and Key Drivers

Parameter	Details
Market Size (2022)	Estimated at approximately USD 830 million, with projected CAGR of 5.2% (2023-2028) [1].
Population	~4.4 million, with a median age of 29 years, increasing healthcare demands.
Healthcare Spending	USD 1.2 billion annually; rising due to public and private sector investments.
Key Drivers	Aging population, rising chronic disease prevalence, healthcare expansion initiatives.
Import Dependence	Over 95% of pharmaceuticals are imported, primarily from the US, Europe, and Asia [2].

Market Segmentation: Branded vs. Generic Drugs

Segment	Market Share (2022)	Growth Drivers	Pricing Dynamics
Branded Drugs	Approx. 60%	Innovation, physician prescribing habits	Premium pricing, limited price controls
Generic Drugs	Approx. 40%	Cost containment, government initiatives	Highly price-sensitive, regulatory incentives

Regulatory Framework in Panama

Approval and Registration Process

Managed by the Panama National Authority for Medicines and Food (AIMA), under the Ministry of Health (MINSA).
Registration Timeline: Typically 6-12 months, involving dossier submission, bioequivalence or bioavailability studies for generics, and quality assurance assessments.
Documentation Required: Quality data, manufacturing certifications, safety and efficacy studies, and labels in Spanish [3].

Market Entry Pathways

Type of Drug	Regulatory Pathway	Key Considerations
Branded Drugs	New chemical entities require full dossier review; imported medicines seek registration with local approval	Emphasis on patent status, clinical data, and compliance with local standards
Generic Drugs	Abbreviated pathway based on reference product approval	Demonstration of bioequivalence, dossier review, and GMP compliance

Key Regulatory Challenges

Limited local manufacturing leading to dependency on imports.
Stringent import licensing and customs procedures.
Price control policies affecting profit margins.
Lack of harmonization with regional standards, complicating regional market access.

Intellectual Property and Patent Landscape

Panama adheres to TRIPS agreements but has historically issued compulsory licenses [4].
Patent term generally 20 years, with limited data exclusivity provisions.
Patent challenges may delay generic market entry.

Market Opportunities for Branded and Generic Drugs

Opportunities

Growing Chronic Disease Burden: Diabetes, hypertension, and cancer drive demand for specialty pharmaceuticals.
Regional Trade Hub: Panama's strategic geographic location facilitates import-export operations.
Affordable Entry via Generics: Price-sensitive market favors generics, especially under government procurement programs.
Public Health Initiatives: Government campaigns for vaccination, HIV/AIDS, and maternal health expand market avenues.
Evolving Regulatory Environment: Opportunities to shape flexible registration pathways aligning with international standards.

Potential for Local Manufacturing

Incentives in Free Trade Zones (e.g., Panama Pacific Free Trade Zone) for pharmaceutical assembly.
Transfer of technology and partnership opportunities with foreign manufacturers.

Key Challenges in Panama's Pharmaceutical Market

Challenge	Implications	Strategic Response
Regulatory Complexity	Delays in market entry, increased costs	Invest in local regulatory expertise, early engagement with AIMA
Price Regulation	Squeeze on profit margins, especially for generics	Develop competitive pricing strategies, align with local pricing policies
Limited Local Production	Heavy reliance on imports, supply chain vulnerabilities	Explore manufacturing partnerships, local registration pathways
Patent and IP Constraints	Barriers to patent-expired drug entry	Monitor patent landscapes, strategize around patent expiration dates
Market Fragmentation	Diverse healthcare providers, variable procurement standards	Tailor market entry strategies to public and private sectors

Comparative Analysis: Panama vs. Regional Markets

Parameter	Panama	Costa Rica	Colombia	Peru
Market Size (USD)	830 million	1.3 billion	2.4 billion	1.1 billion
Regulatory Stringency	Moderate	Stringent	Moderate	Moderate
Generic Market Penetration	40%	50%	45%	40%
Intellectual Property Laws	TRIPS compliant; some exceptions	Strong IP enforcement	TRIPS compliant	TRIPS compliant
Price Control Policies	Yes	Yes	Limited	Yes

Regulatory Opportunities and Strategic Recommendations

Opportunity	Details	Strategic Action
Streamlined Registration for Generics	Enhanced reliance on bioequivalence studies	Engage early with AIMA, prepare comprehensive dossiers
Regional Harmonization	Alignment with PAHO and WHO standards	Advocate for regional regulatory convergence
Public-Private Partnerships (PPPs)	Government procurement and health initiatives	Collaborate on supply for public health programs
Incentives for Local Manufacturing	Free Trade Zones, tax incentives	Establish manufacturing hubs within free trade zones
Digital Regulatory Platforms	Increasing digitization	Leverage e-registration and tracking tools

Concluding Analysis

Panama’s pharmaceutical landscape offers significant opportunities rooted in regional trade, increasing health demands, and strategic positioning. The expanding use of generics aligns with government policies aimed at cost containment, while the market’s openness to branded drugs remains lucrative for innovative products. Nonetheless, navigating the regulatory environment demands proactive engagement, meticulous dossier preparation, and strategic local partnerships. Enhancing local manufacturing, advocating for regulatory harmonization, and understanding pricing policies are pivotal for sustained success.

Key Takeaways

Market Growth: Expect steady expansion driven by demographics and healthcare infrastructure.
Regulatory Strategy: Engage early with AIMA, and adapt dossiers to local requirements, emphasizing bioequivalence for generics.
Pricing Dynamics: Be prepared for price controls, especially in generics; consider strategic pricing models.
Local Production: Opportunities exist via Free Trade Zones and public-private alliances.
Intellectual Property: Monitor patent landscapes to plan timely drug launches, especially post-patent expiry.

Frequently Asked Questions (FAQs)

1. What are the primary regulatory hurdles for new pharmaceutical entrants in Panama?

New entrants face complex registration procedures, requiring thorough dossier submissions and compliance with local standards. Navigating customs and import licensing processes also poses challenges, especially for unregistered or unapproved products.

2. How does Panama’s regulatory environment affect generic drug market access?

Generics benefit from abbreviated pathways, primarily demonstrating bioequivalence. However, registration delays and adherence to quality standards can still impact timing and market entry costs.

3. Are there incentives to manufacture pharmaceuticals locally in Panama?

Yes. Free Trade Zones provide tax and customs advantages, making local manufacturing economically attractive for established and new pharmaceutical companies, especially when paired with technology transfer agreements.

4. How do price control policies influence pharmaceutical profitability in Panama?

Government-imposed price caps, especially on generics, compress margins. Companies should develop targeted strategies, including cost-efficiency measures and value-based pricing, to maintain profitability.

5. What strategies can optimize market penetration for innovative branded drugs?

Engagement with healthcare providers, awareness campaigns, and working within regulatory frameworks to facilitate market entry are crucial. Establishing local collaborations and educational initiatives can also accelerate adoption.

References

[1] Market Research Future, “Panama Pharmaceutical Market Analysis,” 2022.
[2] Panama Ministry of Health, “Pharmaceutical Imports Data,” 2022.
[3] Panama National Authority for Medicines and Food (AIMA), “Guidelines for Drug Registration,” 2022.
[4] World Trade Organization, “TRIPS Agreement and Panama,” 2022.

In conclusion, navigating Panama’s pharmaceutical market necessitates strategic due diligence, regulatory agility, and an understanding of regional dynamics. Companies that adapt to the evolving regulatory landscape and leverage local manufacturing opportunities will be well-positioned for sustainable growth.

List of Branded Drugs Expiring in Q2 2026

Context and Regulatory Environment

Market Implications

Strategic Considerations

Anticipated Timeline

Summary

Key Takeaways

FAQs

Executive Summary

Market Overview: Size, Growth Dynamics, and Key Drivers

Market Segmentation: Branded vs. Generic Drugs

Regulatory Framework in Panama

Approval and Registration Process

Market Entry Pathways

Key Regulatory Challenges

Intellectual Property and Patent Landscape

Market Opportunities for Branded and Generic Drugs

Opportunities

Potential for Local Manufacturing

Key Challenges in Panama's Pharmaceutical Market

Comparative Analysis: Panama vs. Regional Markets

Regulatory Opportunities and Strategic Recommendations

Concluding Analysis

Key Takeaways

Frequently Asked Questions (FAQs)

1. What are the primary regulatory hurdles for new pharmaceutical entrants in Panama?

2. How does Panama’s regulatory environment affect generic drug market access?

3. Are there incentives to manufacture pharmaceuticals locally in Panama?

4. How do price control policies influence pharmaceutical profitability in Panama?

5. What strategies can optimize market penetration for innovative branded drugs?

References

Make Better Decisions: Try a trial or see plans & pricing